Debate: Can biomarkers beyond MSI direct immunotherapy in GI malignancies? - No

Debate: Can biomarkers beyond MSI direct immunotherapy in GI malignancies? - No

imedex

3 years
183 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
In this presentation from "Great Debates and Updates in GI Malignancies 2016", Dr. Howard S. Hochster argues that biomarkers beyond MSI cannot direct immunotherapy in gastrointestinal malignancies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
Up Next Autoplay
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
5 Views
imedex 3 weeks
CAR-T: Management of Cytokine Release Syndrome and Neurotoxicity
CAR-T: Management of Cytokine Release Syndrome and Neurotoxicity
Category: Lymphoma
1,010 Views
imedex 5 months
Update: Relapsed/Refractory Follicular Lymphoma
Update: Relapsed/Refractory Follicular Lymphoma
Category: Lymphoma
388 Views
imedex 5 months
Follicular Lymphoma: Update on Upfront and Maintenance Therapy
Follicular Lymphoma: Update on Upfront and Maintenance Therapy
Category: Lymphoma
326 Views
imedex 5 months
CAR-T in Lymphoma
CAR-T in Lymphoma
Category: Lymphoma
241 Views
imedex 5 months
Peripheral T-Cell Lymphoma: What is New on the Horizon?
Peripheral T-Cell Lymphoma: What is New on the Horizon?
Category: Lymphoma
227 Views
imedex 5 months
AML Case: A 54-year-old woman is in remission but MRD+
AML Case: A 54-year-old woman is in remission but MRD+
Category: Acute Myelogenous Leukemia
115 Views
imedex 6 months
Update: New Drugs for AML
Update: New Drugs for AML
Category: Acute Myelogenous Leukemia
177 Views
imedex 6 months
R/R High Risk CLL: Personalized Management Based on Patient Characteristics and Cytogenetics
R/R High Risk CLL: Personalized Management Based on Patient Characteristics and Cytogenetics
Category: Chronic Lymphocytic Leukemia
163 Views
imedex 6 months
CLL: Sequencing Monotherapy vs. Combination Therapy
CLL: Sequencing Monotherapy vs. Combination Therapy
Category: Chronic Lymphocytic Leukemia
88 Views
imedex 6 months